PF-3644022 NEW
| Price | $31 | $113 | $213 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: PF-3644022 | CAS No.: 1276121-88-0 |
| Purity: 99.12% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | PF-3644022 |
| Description | PF-3644022 is an effective, selective, and ATP-competitive MAPKAPK2 (MK2) inhibitor (IC50: 5.2 nM and a Ki of 3 nM). PF-3644022 potently inhibits TNFα production and has an anti-inflammatory effect. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) (IC50s: 53 nM and 5.0 nM, respectively). |
| In vitro | PF-3644022 potently inhibits TNFα production with similar activity (IC50 of 160 nM), in the human U937 monocytic cell line or peripheral blood mononuclear cells. PF-3644022 blocks TNFα and IL-6 production in LPS-stimulated human whole blood (IC50: 1.6 and 10.3 μM, respectively). The inhibitory activity of PF-3644022 against other MAPKAP kinase family members is evaluated. Other than MNK2 with an IC50 of 148 nM, other family members are largely not inhibited, showing at least several hundred-fold selectivity versus MK2[1]. |
| In vivo | PF-3644022 (3-100 mg/kg; oral gavage; twice daily for 12 days; Lewis rats) treatment exhibits dose-dependent inhibition of chronic paw swelling, measured on day 21 post-treatment (ED50: 20 mg/kg)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 30 mg/mL (80.12 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3 mg/mL (8.01 mM), Solution. 10% DMSO+90% Saline : < 3 mg/mL (8.01 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. |
| Keywords | TNFα | SerineProtease | Serine Protease | safety | PRAK | PF-3644022 | PF3644022 | PF 3644022 | p38MAPK | p38 MAPK | orally | monocytic | MK3 | MK2 | Mitogen-activated protein kinase activated protein kinase 2 | MAPKAPK2 (MK2) | MAPKAP kinase 2 | MAPK activated protein kinase 2 | MAP kinase activated protein kinase 2 | lipopolysaccharide | Inhibitor | inhibit | IL-6 | efficacious | Anti-inflammatory |
| Inhibitors Related | Undecane | Esculin | Bisphenol A | AEBSF hydrochloride | Fumaric acid | Imidazole | Subtilisin | D-Psicose | Proteinase K | Afatinib | Ac-Ala-OH | Sodium new houttuyfonate |
| Related Compound Libraries | Osteogenesis Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Protease Inhibitor Library | Pyroptosis Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
|
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-05 | ||
| $5.00 |
VIP8Y
|
Jinan Finer Chemical Co., Ltd
|
2026-07-03 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY